P-26 HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)

Autor:	J. Tabernero, E. Elimova, G. Ku, K. Shitara, L. Shen, T. Liu, X. Lin, L. Boyken, H. Li, J. Grim, J. Ajani
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S256
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2022.04.117
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d1f07054d531f06ac9030bc01b341c7c https://doi.org/10.1016/j.annonc.2022.04.117 Zobrazit plný text záznamu